These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35146824)

  • 1. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis.
    Takenaka Y; Oya R; Kitamiura T; Ashida N; Shimizu K; Takemura K; Yamamoto Y; Uno A
    Head Neck; 2018 Mar; 40(3):647-655. PubMed ID: 29076207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.
    Matsumura S; Kaira K; Kuba K; Inoue H; Hamada M; Yamazaki T; Nakahira M; Ebihara Y
    Anticancer Res; 2024 Sep; 44(9):4049-4056. PubMed ID: 39197909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
    Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Hagiwara K; Matsuki T; Okada T; Fushimi C; Kondo T; Takahashi H; Okamoto I; Tokashiki K; Hanyu K; Kishida T; Ito T; Yamashita G; Tsukahara K; Masubuchi T; Tada Y; Momiyama K; Yaguchi R; Oridate N; Omura GO; Yamashita T
    Anticancer Res; 2024 Sep; 44(9):4057-4072. PubMed ID: 39197913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
    Yang L; Huang Y; Zhou L; Dai Y; Hu G
    Head Neck; 2019 May; 41(5):1525-1535. PubMed ID: 30597654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
    Nenclares P; Gunn L; Soliman H; Bover M; Trinh A; Leslie I; Wong KH; Melcher A; Newbold K; Nutting CM; Ap Dafydd D; Bhide SA; Harrington K
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection.
    Wang S; Feng Y; Xie Y; Zhao X; Ma J; Liu X; Hu C; Hou T
    Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4541-4548. PubMed ID: 35462579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
    Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.
    Tham T; Wotman M; Chung C; Ahn S; Dupuis H; Gliagias V; Movsesova T; Kraus D; Costantino P
    Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2913-2922. PubMed ID: 31312922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
    Wu F; Wu LL; Zhu LX
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Dang S; Li X; Liu H; Zhang S; Li W
    Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
    Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang S; Qiu C; Yu H; Xu Y; Xu X
    Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.